CGON - Cg Oncology Inc Options
This page provides comprehensive financial data and performance metrics for CGON (Cg Oncology Inc Options). It includes the stock's last close price, dollar and percentage change, various financial ratios, earnings per share details, insider and institutional ownership, and short interest figures. The data also covers volatility, relative volume, price performance over different periods, and analyst recommendations.
CG Oncology Stock (CGON) Opinions on Director's Massive Share Purchase
Social media discussions are focusing on a CG Oncology (CGON) director's recent acquisition of nearly $25 million in shares, signaling strong internal confidence in the company's clinical pipeline for bladder cancer immunotherapy. This purchase, combined with the company's position on biotech catalyst lists for upcoming Phase 3 data, is seen as a significant indicator of optimism regarding regulatory approvals and combination therapy potential. Insider trading data shows this is the second major personal investment in recent months, alongside institutional investors increasing their holdings, while analysts have set a median price target of $81.5 for CGON.
Insider sale notice: CGON (NASDAQ: CGON) 3,928 shares via exercise
CG Oncology, Inc. (NASDAQ: CGON) filed a Rule 144 notice indicating an intended resale of 3,928 shares related to an exercise of stock options on July 1, 2026, with Morgan Stanley Smith Barney LLC handling the transaction. The filing also discloses prior 10b5-1 sales by James Mulay, totaling 1,964 shares on June 15, 2026, and 15,600 shares on April 17, 2026. These disclosures provide insight into insider trading activities and potential market supply changes for CGON stock.
CG Oncology stock hits all-time high at 75.79 USD
CG Oncology Inc.'s stock recently hit an all-time high of $75.79, and currently trades just below its 52-week high, reflecting a significant 183.58% increase over the past year. Despite this surge, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value. The company has also released promising Phase 2 clinical trial data for its bladder cancer treatment, which led to reiterated Buy ratings and increased price targets from several analysts.
Form PRE 14A CG Oncology Inc For: 29 June By Investing.com
This article reports a Form PRE 14A filing by CG Oncology Inc. for June 29, 2026. The piece is brief, noting the filing and linking it to the company's stock symbol CGON, which experienced a 2.46% increase. The content primarily focuses on financial market data and general news unrelated to the filing.
CG Oncology (CGON) director-affiliated fund adds 371K shares
Seven Fleet Partners LP, an entity linked to CG Oncology director Brian Guan-Chyun Liu, acquired 371,085 shares of CGON common stock for $24.81 million at a price of $66.87 per share on June 25, 2026. This open-market purchase increased Five Fleet Partners LP's indirect holdings to 1,886,236 shares. Although Liu is associated with the entity, he disclaims beneficial ownership beyond his proportionate pecuniary interest.
CG Oncology Insider Bought Shares Worth $24,814,454, According to a Recent SEC Filing
An insider at CG Oncology, Inc. (CGON) recently purchased shares valued at $24,814,454, according to a recent SEC filing. The biopharmaceutical company is focused on developing bladder-sparing therapeutics for bladder cancer, with its product candidate cretostimogene grenadenorepvec currently in clinical development. This transaction comes as the company also announced presentations at major healthcare conferences and reported various clinical trial updates.
CG Oncology, Inc. Actuals & Estimates (NASDAQ:CGON)
This article provides an overview of CG Oncology, Inc. (NASDAQ:CGON) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue for past and upcoming quarters, as well as market capitalization and EBITDA. The company's next earnings report is anticipated on August 7, 2026, and analysts predict a target price range between $80.00 and $108.00.
CG Oncology, Inc. Actuals & Estimates (BOATS:CGON)
This article provides an overview of CG Oncology, Inc. (CGON) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It details the company's stock forecast, historical prices, upcoming earnings report, and recent financial performance like earnings per share, revenue, and net income. The article also confirms that CGON does not pay dividends and lists current employee count and EBITDA figures.
CGON Forecast — Price Target — Prediction for 2027
This article provides a forecast for CG Oncology, Inc. (CGON) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial data like EPS, revenue, and net income, and answers frequently asked questions about the company's stock, market capitalization, and upcoming earnings report. The analysis also covers volatility, employee count, EBITDA, and investment recommendations.
CG Oncology (NASDAQ: CGON) director sells 5,000 shares, exercises options
CG Oncology director Leonard E. Post sold 5,000 shares of common stock at $70.00 per share on June 24, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. On the same date, he exercised a director stock option to acquire 5,000 common shares at an exercise price of $0.60 per share, demonstrating an exercise-and-sell pattern. After these transactions, Post directly owns 5,000 common shares and holds 106,077 director stock options expiring on July 8, 2028.
Form 144: 5,000-share exercise sale reports for CGON (CGON)
A Form 144 filing by Morgan Stanley Smith Barney LLC reports the sale of 5,000 shares of CG Oncology, Inc. common stock, resulting from an option exercise on June 24, 2026. The filing also discloses previous 10b5-1 sales by Leonard Post, totaling 6,000 shares for gross proceeds of $325,000 and $54,500 on June 22, 2026, and June 4, 2026, respectively. The report provides key details regarding the transactions and defines relevant financial terms.
Piper Sandler Maintains CG Oncology(CGON.US) With Buy Rating, Announces Target Price $82
Piper Sandler has reiterated its Buy rating for CG Oncology (CGON.US) and set a price target of $82. This indicates a positive outlook from the analytical firm regarding the company's stock performance.
CG Oncology (NASDAQ: CGON) director exercises options and sells 5,000 shares
CG Oncology director Leonard E. Post exercised options to acquire 5,000 shares at $0.60 per share and subsequently sold these 5,000 shares at $65.00 in an open-market transaction on June 22, 2026. The sale was conducted under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, Post reported holding no directly owned common shares but retained 111,077 director stock options.
Form 144 CG Oncology For: 22 June By Investing.com
This article from Investing.com reports that CG Oncology filed a Form 144 for June 22. The filing is a standard SEC document typically indicating an insider's intent to sell restricted stock. The piece also notes that CG Oncology's stock (CGON) was up 8.46% at the time of publication.
CGON (NASDAQ: CGON) files notice to sell 6,000 shares on 06/22/2026
CG Oncology, Inc. (NASDAQ: CGON) has filed a Rule 144 notice indicating a proposed sale of 6,000 common shares on June 22, 2026, stemming from the exercise of stock options with cash. Additionally, the filing reported a 10b5-1 sale of 1,000 common shares on June 4, 2026, for $54,500 by Leonard E Post. The sentiment surrounding these filings is neutral, as they represent routine transactions with no material corporate events suggested.
CG Oncology Inc (CGON) Institutional Confidence
CG Oncology Inc's institutional shareholding score is 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 105.70%, a decrease of 9.96% quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 444.57K shares, though this represents a 94.64% decrease in their holdings.
CG Oncology Inc (CGON) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for CG Oncology Inc (CGON), highlighting its current earnings forecast score of 8.25 and ranking in the Biotechnology & Medical Research industry. It details analyst ratings, target prices, and future EPS and revenue expectations. Most analysts rate CGON as a "Buy" with an average price target of $68.50.
Cg oncology director James Mulay sells $118,075 in stock By Investing.com
CG Oncology Director James Mulay sold $118,075 worth of company common stock on June 15, 2026, after exercising options to acquire 1,964 shares. These transactions were conducted under a Rule 10b5-1 trading plan. Following the sale, Mr. Mulay holds no direct shares in the company, though he retains 2,620 unexercised Director Stock Options.
Cg oncology director James Mulay sells $118,075 in stock
CG Oncology Director James Mulay sold $118,075 worth of company common stock after exercising options. The sales were conducted at $60.12 per share under a Rule 10b5-1 trading plan. The transactions occurred as CGON shares have seen a 134% surge over the past year, with the company also receiving positive analyst ratings and reporting promising Phase 2 study results.
Cg oncology director James Mulay sells $118,075 in stock By Investing.com
CG Oncology Director James Mulay sold company common stock worth $118,075 on June 15, 2026, executed at $60.12 per share, following an option exercise valued at $18,925. The transactions were conducted under a Rule 10b5-1 trading plan. Despite the stock appearing overvalued according to InvestingPro, CG Oncology has shown positive Phase 2 results for its bladder cancer treatment, leading to reiterations of "Buy" ratings and increased price targets from analysts.
CG Oncology (NASDAQ: CGON) director pre-plans option exercise and share sale
CG Oncology director James Mulay executed an exercise-and-sell transaction, exercising options for 1,964 shares of common stock at strike prices of $12.59 and $3.72, and subsequently selling all 1,964 shares in open-market trades at $60.12 per share. These transactions were pre-arranged under a Rule 10b5-1 trading plan adopted on March 27, 2026. After these transactions, Mulay holds 654 shares of Common Stock and 2,620 derivative securities in Director Stock Options.
CG Oncology (CGON) Valuation Check As Cretostimogene Nears Phase 3 Data And Planned Regulatory Filing
CG Oncology (CGON) is gaining investor attention as it approaches Phase 3 data and regulatory filing for its bladder cancer treatment, cretostimogene, later this year. Despite recent stock volatility, CGON has shown a 31.42% year-to-date return and is flagged as undervalued by some metrics, including an 85.7% discount according to a SWS DCF model, although its P/B ratio is higher than the broader US biotech average. The article advises investors to conduct further research due to mixed sentiment and potential trial risks.
CG Oncology, Inc. (CGON) reports Q1 loss, tops revenue estimates
CG Oncology, Inc. (CGON) announced a Q1 loss per share of $0.66, which is higher than the analyst consensus estimate of a $0.57 loss. Despite the higher-than-expected loss, the company surpassed revenue estimates, reporting $0.23 million against an expectation of $0.05 million. This financial update provides insight into the company's performance for the first quarter.
CG Oncology (CGON) Valuation Check As Cretostimogene Nears Phase 3 Data And Planned Regulatory Filing
CG Oncology (CGON) is gaining investor attention as its bladder cancer therapy, cretostimogene, approaches Phase 3 data release and a planned regulatory filing later this year. Despite recent stock volatility, CGON shares are up 31.42% year-to-date and are seen as undervalued by some metrics, including a significant discount to an estimated future cash flow value. However, the company still faces risks from trial outcomes and ongoing financial losses.
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
CG Oncology (NASDAQ: CGON) is nearing significant milestones for its lead bladder cancer drug, cretostimogene, with Phase 3 PIVOT-006 results expected soon and a regulatory filing targeted for Q4. The company has highlighted strong durability data in BCG-unresponsive NMIBC, demonstrating a 76% complete response rate and sustained responses for up to 24 months, which it believes differentiates its therapy from competitors. With over $1 billion in cash and no debt, CG Oncology is well-resourced through 2029 to pursue commercial readiness and manufacturing for potential launch.
CGON: Pivotal NMIBC trial results and regulatory filings position cretostimogene for first approval
CGON's cretostimogene is moving forward in pivotal trials for Non-Muscle Invasive Bladder Cancer (NMIBC), demonstrating strong clinical durability and competitive differentiation. The company has aligned its regulatory and manufacturing processes for upcoming filings, and its commercial strategy targets key accounts, supported by a financial runway extending through 2029. This information is derived from CG Oncology, Inc.'s Goldman Sachs 47th Annual Global Healthcare Conference 2026 Audio Transcript.
CenterBook Partners LP Sells 326,116 Shares of CG Oncology, Inc. $CGON
CenterBook Partners LP reduced its stake in CG Oncology Inc. by 82.5% in the fourth quarter, selling 326,116 shares and ending with 69,224 shares. Despite this reduction, other institutional investors like JPMorgan Chase & Co. and Clearbridge Investments LLC increased their positions. Analysts have a "Moderate Buy" consensus rating for CG Oncology with an average price target of $81.73, even though the company recently missed EPS expectations.
CG Oncology (NASDAQ: CGON) investors back directors, EY and pay plan
CG Oncology, Inc. (NASDAQ: CGON) held its 2026 annual stockholder meeting where investors re-elected two Class II directors, Christina Rossi and Victor Tong, Jr., and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders also approved the compensation of named executive officers and expressed a preference for annual advisory votes on executive pay, which the company will adopt. The meeting's results, detailed in an 8-K filing, reflect shareholder support for current governance and compensation practices.
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CG Oncology is advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, with a focus on high-risk BCG-unresponsive disease. The company has reported strong complete response rates and significant progress on its Biologics License Application (BLA) submission, anticipating completion of the manufacturing module by year-end. CG Oncology is also preparing for commercial launch, including establishing relationships with urology sites and planning for a sales force, while exploring future market opportunities in intermediate-risk and BCG-exposed patients with additional trials.
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CG Oncology is advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, with a focus on high-risk BCG-unresponsive disease. The company reported promising complete response rates and a good tolerability profile for cretostimogene, with a rolling Biologics License Application (BLA) submission underway. CG Oncology is also preparing for commercial launch, including manufacturing readiness, and exploring future opportunities in BCG-exposed and intermediate-risk patient populations.
Is CG Oncology (CGON) Centralizing Power To Sharpen Commercial Focus Or Stretch Leadership Too Thin?
CG Oncology is undergoing significant leadership changes with CEO Arthur Kuan assuming the President role following the departure of President & COO Ambaw Bellete. This move is seen as an attempt to centralize power and sharpen commercial focus on their primary drug candidate, cretostimogene, as they face current small revenue and substantial losses. While the changes are viewed more as a governance and execution risk to monitor rather than a fundamental shift, the company aims to frame its commercial path at upcoming conferences.
Is CG Oncology (CGON) Centralizing Power To Sharpen Commercial Focus Or Stretch Leadership Too Thin?
CG Oncology is undergoing significant leadership changes with CEO Arthur Kuan assuming the President role and the former President & COO Ambaw Bellete separating from the company. This reshuffle, including a search for a Chief Commercial Officer, aims to strengthen the company's commercial focus on its cretostimogene product. While these changes align with the company's investment narrative, they also introduce governance and execution risks to monitor, especially given the stock's recent pullback.
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CG Oncology highlighted promising data for its lead bladder cancer therapy, cretostimogene, showing a 76% complete response rate in BCG-unresponsive disease with durable responses. The company is progressing with a rolling Biologics License Application (BLA) submission, with clinical and non-clinical modules already filed and the manufacturing module expected by year-end. CG Oncology is also preparing for the therapy's commercial launch and pipeline expansion into other bladder cancer indications, with significant data readouts expected in the coming months.
CGON Technical Analysis & Stock Price Forecast
The technical analysis for CG Oncology Inc (CGON) indicates an overall "Sell" consensus based on a combination of moving averages and oscillators. While the stock is trading above its 200-day moving average, several short-term indicators like MACD and shorter-period simple moving averages suggest a bearish outlook. Key support and resistance levels are identified at $52.693 and $63.643, respectively.
CGON Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of CG Oncology Inc (CGON), detailing its revenue breakdown, profitability margins, and a comparison with competitors CRSP and DNTH. CGON shows significant negative gross, operating, and net margins, indicating challenges in profitability, despite holding a substantial market capitalization of $4.74 billion. The analysis highlights key financial metrics like ROE and suggests areas for competitive benchmarking.
CG Oncology (CGON) director receives 9,354 stock options at $56.09 strike
CG Oncology director Brian Guan-Chyun Liu was granted 9,354 stock options with an exercise price of $56.09 per share, expiring on June 3, 2036. The options vest monthly over time, with 1/12th of the total vesting each month starting June 4, 2026, contingent on his continuous service to the company. This transaction is classified as an equity-based compensation grant rather than an open-market purchase or sale.
CG Oncology (NASDAQ: CGON) director receives 9,354 stock options at $56.09 exercise price
CG Oncology (NASDAQ: CGON) director Victor Edward Tong Jr. was granted 9,354 stock options with an exercise price of $56.09 per share, expiring on June 3, 2036. These options will vest in 12 equal monthly installments starting after June 4, 2026, contingent on his continued service. This transaction is a compensation-related grant, not an open-market purchase or sale of shares.
[Form 4] CG Oncology, Inc. Insider Trading Activity
CG Oncology, Inc. director James Mulay received an option grant for 9,354 shares of common stock with an exercise price of $56.09, expiring on June 3, 2036. The options vest monthly over 12 months starting June 4, 2026, with any remaining unvested portion vesting at the next annual shareholder meeting if it occurs before the first anniversary. This transaction, a grant/award, increases Mulay's direct holdings of stock options to 9,354 shares.
CG Oncology (NASDAQ: CGON) director receives grant of 9,354 stock options at $56.09
CG Oncology director Susan E. Graf was granted 9,354 stock options with an exercise price of $56.09 per share, expiring on June 3, 2036. The options vest in 12 equal monthly installments beginning after June 4, 2026, contingent on her continuous service. This transaction increases her direct holdings to 9,354 director stock options.
CG Oncology (CGON) director Leonard Post sells 1,000 shares, receives new options
CG Oncology, Inc. director Leonard E. Post recently engaged in an exercise-and-sale transaction, selling 1,000 common shares at $54.50 after exercising options at $0.60 per share, as part of a pre-arranged Rule 10b5-1 plan. Post also received a new grant of 9,354 director stock options with an exercise price of $56.09, some of which are immediately vested and others that will vest monthly after June 4, 2026. Following these transactions, Post holds 1,000 common shares and 116,077 director stock options in CG Oncology.
[144] CG Oncology, Inc. SEC Filing
This SEC Form 144 filing indicates a proposed sale of 3,000 shares of CG Oncology, Inc. (CGON) common stock by an unnamed filer. The securities, valued at $163,260.00, were acquired through the exercise of stock options on June 4, 2026, and are intended to be sold on NASDAQ via Morgan Stanley Smith Barney LLC. The filing details the transaction and affirms the filer's lack of knowledge regarding adverse material information about CGON.
Assessing CG Oncology (CGON) Valuation After Executive Shakeup And Commercial Leadership Search
CG Oncology (CGON) recently announced leadership changes, including CEO Arthur Kuan becoming President and a search for a Chief Commercial Officer, following the departure of President and COO Ambaw Bellete. Despite recent share price consolidation, the company shows strong year-to-date and one-year returns, though it faces a net loss and modest revenue. The article assesses CGON's valuation, noting its P/B ratio is higher than the industry average but lower than its direct peers, while its stock trades below analyst targets and significantly below the SWS DCF model estimate.
CGON: Cretostimogene shows durable efficacy and safety in NMIBC, with pivotal data and launch prep ongoing
CG Oncology's cretostimogene, an oncolytic immunotherapy for NMIBC, is demonstrating strong and durable efficacy and safety results. The company is currently undergoing a rolling BLA submission and making commercial preparations for the drug's launch. Key upcoming milestones include pivotal trial data and plans for expanding treatment to broader patient populations.
Assessing CG Oncology (CGON) Valuation After Executive Shakeup And Commercial Leadership Search
CG Oncology has recently undergone a leadership reshuffle, with CEO Arthur Kuan becoming President and a search initiated for a Chief Commercial Officer. This comes after a period of share price consolidation, though the stock still shows strong long-term momentum. The article assesses CGON's valuation using Price-to-Book and Discounted Cash Flow models, noting that while P/B is in line with expectations, the DCF model suggests a significant undervaluation, pointing to potential risks and opportunities for investors.
CG Oncology Leadership Shift Puts Focus On Valuation Gap And Execution
CG Oncology (NasdaqGS:CGON) announced that its President & COO, Ambaw Bellete, will depart, with CEO Arthur Kuan assuming the additional role of President. The company is actively searching for a Chief Commercial Officer, signaling a restructuring of its commercial leadership. This leadership change occurs as CGON stock trades at $62.29, significantly below analyst targets and Simply Wall St's fair value estimate, prompting investors to focus on how the new leadership structure will address commercial execution and the company's valuation gap.
CG Oncology Leadership Shift Puts Focus On Valuation Gap And Execution
CG Oncology has announced a leadership change, with President & COO Ambaw Bellete separating from the company and CEO Arthur Kuan taking on the additional role of President. The company is also searching for a Chief Commercial Officer, signaling a restructuring of its commercial leadership. This transition comes as the stock shows strong long-term performance but recent short-term weakness, prompting investors to focus on how these changes will impact commercial execution and address the significant valuation gap identified by analysts and Simply Wall St.
CGON stock up 60.8% in six months: Here's what you need to know
This article states that CGON stock has seen a significant increase of 60.8% over the past six months. It implies that the article will provide further details on the reasons behind this performance and other relevant information about the company.
CG Oncology to Present at Upcoming Investor Conferences in June
CG Oncology, Inc. announced that its Chairman, President & Chief Executive Officer, Arthur Kuan, will participate in fireside chat presentations at two investor conferences in June: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Interested parties can access live audio webcasts and replays on the company's website. CG Oncology is a late-stage clinical biopharmaceutical company focused on bladder cancer therapeutics.
CG Oncology CEO joins June fireside chats at Jefferies and Goldman Sachs
CG Oncology (NASDAQ: CGON) announced that its Chairman, President, and CEO, Arthur Kuan, will participate in fireside chats at two major healthcare investor conferences in June 2026. He is scheduled to speak at the Jefferies Global Healthcare Conference on June 3rd in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th in Miami, with webcasts available for investors. The company is a late-stage clinical biopharmaceutical company focused on developing immunotherapies for bladder cancer.
